Anterior chamber IOLs lasts longer

Article

Anterior chamber intraocular lenses (IOLs) last twice as long as posterior chamber IOLs, before they need to be replaced.

Anterior chamber intraocular lenses (IOLs) last twice as long as posterior chamber IOLs, before they need to be replaced, according to a study published in the February issue of the Journal of Cataract and Refractive Surgery.

Frederico F. Marques and colleagues from the Complexe Hospitalar Padre Bento de Guarulhos, Brazil, reviewed the outcomes of 49 subjects who had undergone IOL exchange between 1986 and 2002. Fifteen patients had been implanted with an anterior chamber IOL and 34 with a posterior chamber IOL.

The mean interval between first surgery and lens exchange was 83.2 months in the anterior chamber group and 37.9 months in the posterior chamber group. The main reason for exchange in the anterior chamber group was inflammation resulting from uveitis-glaucoma-hyphaema syndrome or persistent iritis. In contrast, posterior chamber IOLs were more likely to become decentred or dislocated.

Best corrected visual acuity (BCVA) in the anterior chamber group, after exchange, improved in nine eyes (60%), was stable in four (27%) and worsened in two (13%). In the posterior chamber group, BCVA imporved in 17 eyes (50%), was stable in 11 (32%) and worsened in six (18%).

The researchers concluded that anterior chamber IOLs are able to last twice as long as posterior chamber IOLs.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.